The company operates a business-to-business travel platform that provides travel agents and corporate clients with access to airline ticket inventory, booking technology, and credit facilities.
The company lacks a durable moat as evidenced by its low take rate of 2.68% and declining margins despite high revenue growth. While it claims a technology edge, the business is essentially a low-margin intermediary in a highly competitive and fragmented travel distribution market.
Management has prioritized aggressive expansion and acquisitions, such as GITHM Private Limited, using equity issuance. However, the high revenue growth has not translated into earnings growth, with EPS declining significantly, suggesting poor returns on reinvested capital.
The company's aggressive pursuit of scale through acquisitions and equity dilution finally hit a wall as the underlying unit economics remained broken. Despite massive revenue growth, the inability to generate positive cash flow or earnings meant the business was essentially running on a treadmill that required constant external capital to stay upright. Over five years, the combination of rising management pay, related-party leakage, and a bloated receivables cycle exhausted shareholder patience, leading to a collapse in the share price as the market realized the 'technology edge' was merely a low-margin brokerage service with no pricing power.
RichFakir rates TSC India Ltd's business quality as poor — 35/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, TSC India Ltd is trading about 1% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on TSC India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of TSC India Ltd's fair value is about ₹38 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →